RxDoctor Payments Data

Sarah Peterman

Nurse Practitioner · Lemoyne, PANPI 1053876144

Payments from drug & device makers

$4,635in general payments, 2019–2025

Across 49 payments — averaging $94.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • GSK$1K
  • Harmony Biosciences LLC$520
  • AstraZeneca$168
  • Jazz Pharmaceuticals Inc.$125
  • Verona Pharma, Inc.$125
  • plus $172 from 4 others

What the payments were for

  • Travel & lodging$2,17747%
  • Food & beverage$2,22548%
  • Education$2335%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,635 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,173
Medicare patients
175
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter234$202,073
Dupixent PenDupilumab17$62,340
Breztri AerosphereBudesonide/Glycopyr/Formoterol73$59,059
Breo ElliptaFluticasone/Vilanterol65$47,311
Spiriva RespimatTiotropium Bromide30$30,387
Stiolto RespimatTiotropium Br/Olodaterol Hcl36$20,134
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$15,442
Combivent RespimatIpratropium/Albuterol Sulfate15$7,322
Bevespi AerosphereGlycopyrrolate/Formoterol Fum16$6,739
Advair HfaFluticasone Propion/Salmeterol15$6,173
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$5,693
Dexlansoprazole DrDexlansoprazole23$4,287
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,096
SymbicortBudesonide/Formoterol Fumarate13$3,705
Albuterol Sulfate HfaAlbuterol Sulfate107$3,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,233$264,827331 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$168$69,502102 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$97$57,84481 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Lemoyne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →